Articles tagged "Efficacy"

2016 American Transplant Congress
An Economical and Effective Vaccination Program in Patients Transplanted for Hepatitis B Virus Related Liver Diseases: A Prospective Study.
W. Ju, A. Yang, Q. Ren, D. Wang, Z. Guo, Y. Ma, A. Hu, Q. Tai, X. Zhu, X. He.
Organ Transplantation Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
Aims: To prospectively investigate the efficacy and safety of procedural HBV vaccination in patients transplanted for HBV related liver diseases for prevention of hepatitis B…
2016 American Transplant Congress
Effect of Donor-Recipient Gender Mismatch in Liver Transplant Recipients: A Post-Hoc Analysis of the H2304 Study.
L. Fischer, P. de Simone, G. Dong, P. Lopez, P. Bernhardt, F. Saliba.
H2304 study group, Hamburg, Germany.
Purpose: Donor-recipient gender mismatch may play a role in liver transplant (LTx) outcomes. Here we present the 24-month results from the post-hoc analysis of the…
2016 American Transplant Congress
Assessment of Transplant Health Literacy of Liver Transplant Candidates and Their Caregivers.
Y. Bababekov,¹ Z. Fong,^1,2 J. Adler,¹ H. Yeh,¹ D. Chang,^1,2 J. Pomposelli.³
¹Surgery, Massachusetts General Hospital/Harvard Medical School, Boston, MA; ²Codman Center for Clinical Effectivness in Surgery, Massachusetts General Hospital/Harvard Medical School, Boston, MA; ³Transplantation, Lahey Hospital and Medical Center, Burlington, MA.
Purpose: All transplant programs provide education sessions and instructional material to their patients to improve health literacy. However, their efficacy is unknown. We piloted a…
2016 American Transplant Congress
Long-Term vs Short-Term Valganciclovir Prophylaxis Use for Cytomegalovirus and Epstein-Barr Virus Infections in Pediatric Living Related Liver Transplantation.
T. Ueno,¹ H. Yamanaka,¹ Y. Takama,¹ N. Tanaka,¹ Y. Tazuke,¹ K. Bessho,² H. Okuyama.¹
¹Pediatric Surgery, Osaka University Graduate School of Medicine, Suita, Japan; ²Pediatrics, Osaka University Graduate School of Medicine, Suita, Japan.
[Purpose] Cytomegalovirus (CMV) and Epstein-Barr virus (EBV) infections are the most important viral infections in pediatric patients with transplant. Valganciclovir (VGCV) has been used as…
2015 American Transplant Congress
Efficacy of Low Dose Chemoprophylaxis for Coccidioidomycosis Infection in Liver Transplantation Recipients
R. El Ramahi,² S. Habib,¹ S. Rosen,³ S. Farran,³ C. Walker,³ J. Shubeilat,⁴ S. Yost,⁵ O. McCotter,⁶ M. Cassal,⁶ A. Rana,⁷ T. Boyer,¹ T. Zangeneh.²
¹Liver Research Institute, Divisions of Gastroenterology, Hepatology and Transplantation, Department of Medicine, University of Arizona, Tucson, AZ; ²Division of Infectious Disease, Department of Medicine, University of Arizona, Tucson, AZ; ³Internal Medicine Residency Program, Department of Medicine, University of Arizona, Tucson, AZ; ⁴Division of Infectious Disease, Department of Medicine, University of Massachusetts, Worcester, MA; ⁵Division of Transplantation, School of Pharmacy, University of Arizona, Tucson, AZ; ⁶Office of Border Health, Arizona Department of Health Services, Tucson, AZ; ⁷Division of Transplantation, Department of Surgery, University of Arizona, Tucson, AZ.
Introduction:Coccidioidomycosis(CM) infection rate of 6.9% has been reported in solid organ transplantation recipients living in endemic Southwestern U.S.Aim:Assess the risk of CM infection in liver…
2015 American Transplant Congress
Targeting Complement Pathways During Ischemia and Reperfusion: Implications for the Prevention of Delayed Graft Function
Z. Yu,¹ S. Qi,² M. Lasaro,¹ K. Bouchard,¹ C. Dow,¹ K. Moore,¹ Z. Wu,² A. Barama,² J. Xu,² K. Johnson,¹ A. Marozsan,¹ Y. Wang.¹
¹Pre-Clinical Sciences, Alexion Pharmaceutical Inc., Cheshire, CT; ²Department of Surgery, Hôpital Notre Dame and Université de Montréal, Montréal, QC, Canada.
Complement system plays a critical role in ischemia-reperfusion injury (IRI), and contributes to DGF. The aim of this study was to evaluate the effects of…
2015 American Transplant Congress
Early Conversion to Everolimus in De Novo Kidney Transplant Recipients: 12-Month Results from the ELEVATE Study
J. de Fijter, H. Holdaas, A. Speziale, G. Junge, Z. Wang, J. Cruzado, M. van der Giet.
For the ELEVATE Study, Leiden, Netherlands.
Purpose: Long-term exposure to calcineurin inhibitors (CNIs) contributes to unfavorable long-term outcomes, including inferior renal function and premature graft loss with vascular lesions, glomerulosclerosis and…
2015 American Transplant Congress
Everolimus and Early Calcineurin Inhibitor Withdrawal Is Associated With Superior Renal Function: 5-Year Follow-Up of the Randomized PROTECT Liver Transplantation Study
M. Sterneck, G. Kaiser, N. Heyne, N. Richter, F. Rauchfuss, A. Pascher, P. Schemmer, L. Fischer, C. Klein, S. Nadalin, F. Lehner, U. Settmacher, D. Gotthardt, M. Loss, S. Ladenburger, P. Wimmer, M. Dworak, H. Schlitt.
PROTECT Study Group, Novartis Pharma GmbH, Germany.
Purpose: At the end of the 12-month (M) PROTECT core study (NCT00378014), de novo liver transplant recipients (LTxR) who switched from a calcineurin inhibitor (CNI)…
2015 American Transplant Congress
Treatment of Hepatitis C Virus in Kidney Transplant Recipients With Direct Acting Anti-Viral Agents: Early Results in 12 Cases
A. Sharfuddin,¹ T. Taber,¹ M. Mujtaba,¹ M. Yaqub,¹ D. Mishler,¹ P. Kwo,² R. Vuppalanchi.²
¹Medicine/Nephrology, Indiana University, Indianapolis; ²Medicine/Hepatology, Indiana University, Indianapolis.
Background: Recently approved direct acting antiviral agents (DAA) for treatment of HCV are interferon sparing allowing an attractive treatment option for kidney transplant recipient with…
2015 American Transplant Congress
Efficacy and Safety of Once-Daily Everolimus With Minimized Once-Daily Tacrolimus After Liver Transplantation
P. De Simone,¹ P. Carrai,¹ L. Coletti,¹ A. Precisi,² D. Campani,³ F. Filipponi.¹
¹Hepatobiliary Surgery and Liver Transplantation, University of Pisa Medical School Hospital, Pisa, Italy; ²Laboratory, University of Pisa Medical School Hospital, Pisa, Italy; ³Pathology, University of Pisa Medical School Hospital, Pisa, Italy.
Background: The everolimus (EVR) pharmacokinetic profile allows for its once daily (OD) administration. We tested the efficacy and safety of a combination schedule of OD-EVR…